Pharma Influence at the FDA

Email Print
FacebookTwitterShare

An interesting anecdote:

[A] researcher Sanjay Kaul was removed from the panel after prasugrel’s manufacturer Eli Lilly complained about research papers in which he questioned the drug’s safety.
The drug ended up being approved by the panel by nine votes for versus none against.

So who thinks transparency in panel selection will actually improve drug safety? Government bureaucracies encourage this type of corruption, and “transparency” will not change that.

11:35 pm on February 24, 2009
  • LRC Blog

  • LRC Podcasts